Henan Lingrui Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
Henan Lingrui Pharmaceutical has a total shareholder equity of CN¥2.9B and total debt of CN¥12.5M, which brings its debt-to-equity ratio to 0.4%. Its total assets and total liabilities are CN¥4.9B and CN¥2.0B respectively. Henan Lingrui Pharmaceutical's EBIT is CN¥709.0M making its interest coverage ratio -11.2. It has cash and short-term investments of CN¥956.8M.
Key information
0.4%
Debt to equity ratio
CN¥12.53m
Debt
| Interest coverage ratio | -11.2x |
| Cash | CN¥956.81m |
| Equity | CN¥2.90b |
| Total liabilities | CN¥1.98b |
| Total assets | CN¥4.89b |
Recent financial health updates
Recent updates
Does Henan Lingrui Pharmaceutical (SHSE:600285) Have A Healthy Balance Sheet?
Nov 30
An Intrinsic Calculation For Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Suggests It's 44% Undervalued
Oct 28Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Surges 33% Yet Its Low P/E Is No Reason For Excitement
Oct 13If EPS Growth Is Important To You, Henan Lingrui Pharmaceutical (SHSE:600285) Presents An Opportunity
Aug 07A Look At The Fair Value Of Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285)
Jul 03Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Stock Catapults 27% Though Its Price And Business Still Lag The Market
May 07Henan Lingrui Pharmaceutical's (SHSE:600285) Earnings May Just Be The Starting Point
May 02Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Held Back By Insufficient Growth Even After Shares Climb 27%
Mar 04Should You Be Adding Henan Lingrui Pharmaceutical (SHSE:600285) To Your Watchlist Today?
Feb 29Financial Position Analysis
Short Term Liabilities: 600285's short term assets (CN¥2.3B) exceed its short term liabilities (CN¥1.9B).
Long Term Liabilities: 600285's short term assets (CN¥2.3B) exceed its long term liabilities (CN¥66.0M).
Debt to Equity History and Analysis
Debt Level: 600285 has more cash than its total debt.
Reducing Debt: 600285's debt to equity ratio has reduced from 9% to 0.4% over the past 5 years.
Debt Coverage: 600285's debt is well covered by operating cash flow (5226.3%).
Interest Coverage: 600285 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 22:35 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Henan Lingrui Pharmaceutical Co., Ltd. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Bo Chen | Chasing Securities |
| Yang Luo | CLSA |